Journal Mobile Options
Table of Contents
Vol. 47, Suppl. 2, 2001
Issue release date: 2001
Chemotherapy 2001;47(suppl 2):1–29
(DOI:10.1159/000049157)

Somatostatin Analogs for Cancer Treatment and Diagnosis: An Overview

Scarpignato C. · Pelosini I.
aDepartment of Internal Medicine, School of Medicine and Dentistry, University of Parma, Italy; bDepartment of Gastroenterology and Hepatology, Faculty of Medicine, University of Nantes, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Due to the limited efficacy and considerable toxicity of conventional chemotherapy, novel cytotoxic agents and innovative noncytotoxic approaches to cancer treatment are being developed. Amongst the various hormonal agents, increasing attention is being directed to somatostatin analogs. This is largely due to the demonstration of antineoplastic activity of these compounds in a variety of experimental models in vitro and in vivo and to the elucidation of some aspects of the molecular mechanisms underlying their antineoplastic activity. On the other hand, clinical experience with somatostatin analogs in the treatment of conditions like acromegaly and GEP tumors has shown that they are well tolerated compared to other antineoplastic therapies currently in use. As a consequence, there is much ongoing clinical research to determine whether or not results from experimental studies will translate into clinically useful antineoplastic activity. Besides being used in cancer treatment and palliation, radiolabelled somatostatin analogs are employed for the localization of primary and metastatic tumors expressing somatostatin receptors. The so-called ‘somatostatin receptor scintigraphy’ is indeed the most important clinical diagnostic investigation for patients with suspected neuroendocrine tumors. Targeted radiotherapy, which is being evaluated in clinical trials, represents an obvious extension of somatostatin scintigraphy. Since the short half-life of native somatostatin makes continuous intravenous infusion mandatory, several long-acting analogs have been synthesized. Amongst the hundreds of peptides synthesized, octreotide (which binds mainly to SSTR-2 and SSTR-5 receptor subtypes) has been the most extensively investigated. A thorough analysis of the pharmacological activities and therapeutic efficacy of the native somatostatin and the synthetic analogs (octreotide, lanreotide and vapreotide) reveals that the biological actions of these peptides are not always identical. These differences appear to be related to the different affinities of the natural hormone and synthetic derivatives for the different receptor subtypes. For all the three peptides long-lasting formulations have been developed to provide patients with the convenience of once or twice a month administration and to ensure stable drug serum concentrations between injections. Radiolabelled derivatives of octreotide, lanreotide and vapreotide have been synthesized and used as radiopharmaceuticals for somatostatin receptor scintigraphy and somatostatin receptor-targeted radiotherapy. The safety profile of synthetic somatostatin analogs is well established. Most adverse reactions to these peptides are merely a consequence of their pharmacological activity and consist mainly of gastrointestinal complaints, cholelithiasis and effects on glucose metabolism. They are often of little clinical relevance, thus making somatostatin analogs safe drugs for long-term use. While immediate release preparations are the drugs of choice in the short term, long-acting formulations are better indicated, on an outpatient basis, for the long-term management of chronic conditions. New ‘receptor-selective’ and ‘universal’ somatostatin analogs are being developed and combinations of currently available derivatives with other (cytotoxic and/or hormonal) agents are being explored in the search for an efficacious and well-tolerated treatment of the various malignancies. Somatostatin receptor-targeted chemotherapy (with conjugates of somatostatin peptides with cytotoxic drugs) and gene therapy (e.g. transferring the SSTR-2 gene into neoplastic cells), which have been successfully tested in experimental studies, should be applied to human beings in a not too distant future.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Devita VT: Principles of cancer management: Chemotherapy; in Devita VT, Rosenberg SA, Hellman S (eds): Cancer. Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott Williams & Wilkins, 1997, pp 333–347.
  2. Fisher DS, Tish Knobf M, Durivage HJ, Tish Knobf M: The Cancer Chemotherapy Handbook. St Louis, Mosby-Year Book, 1997, pp 1–530.
  3. Baquiran DC, Gallagher J: Lippincott’s Cancer Chemotherapy Handbook, ed 5. Philadelphia, Lippincott Williams & Wilkins, 1998, pp 1–384.
  4. Skeel RT: Handbook of Cancer Chemotherapy, ed 5. Philadelphia, Lippincott Williams & Wilkins, 1999, pp 1–720.
  5. Schally AV: Oncological applications of somatostatin analogs. Cancer Res 1988;48:6877–6885.
  6. Lamberts SWJ, Krenning EP, Reubi JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450–482.
  7. Weckbecker G, Stolz B, Susini C, Bruns C: Antiproliferative somatostatin analogues with potential in oncology; in Lamberts SWJ (ed): Octreotide: The Next Decade. Bristol, Bioscientifica, 1999, pp 339–352.
  8. Höffken K: Peptides in Oncology. II. Somatostatin Analogues and Bombesin Antagonists. Berlin, Springer, 1993, pp 1–136.
  9. Reubi JC: Octreotide and nonendocrine tumors: Basic knowledge and therapeutic potential; in Scarpignato C (ed): Octreotide: From Basic Science to Clinical Medicine. Basel, Karger, 1996, pp 256–269.
  10. Robbins RJ: Somatostatin and cancer. Metab Clin Exp 1996;45(suppl):98–100.
  11. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R: Somatostatin analogs: Angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997;15:77–86.
  12. Kath R, Höffken K: The significance of somatostatin analogues in the antiproliferative treatment of carcinomas; in Höffken K (ed): Peptides in Oncology III. Berlin, Springer, 2000, pp 23–43.
  13. Yamada T, Creutzfeldt W, Beglinger C, Chiba T: Working Team Report: The effect of somatostatin on cellular proliferation. Gastroenterol Int 1994;7:13–23.
  14. Pollak MN, Schally AV: Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217:143–152.

    External Resources

  15. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C: Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001;47(suppl 2):30–39.
  16. Öberg K: Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001;47(suppl 2):40–53.
  17. Scarpignato C, Camboni MG: Safety profile of octreotide; in Scarpignato C (ed): Octreotide: From Basic Science to Clinical Medicine. Basel, Karger, 1996, pp 296–309.
  18. Kwekkeboom DJ, Krenning EP, Lamberts SWJ: The role of octreotide scintigraphy in clinical diagnosis and therapy; in Scarpignato C (ed): Octreotide: From Basic Science to Clinical Medicine. Basel, Karger, 1996, pp 281–294.
  19. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi J-C: Somatostatin receptor scintigraphy. Nucl Med Ann 1995;1:1–50.
  20. O’Byrne KJ, Carney DN: Radiolabelled somatostatin analogue scintigraphy in oncology. Anticancer Drugs 1996;7(suppl 1):33–44.
  21. Virgolini I: Vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumor patients. Eur J Clin Invest 1997;27:793–800.
  22. Wiseman GA, Kvols LK: Therapy of neurometastatic tumors with radiolabelled MIBG and somatostatin analogues. Semin Nucl Med 1995;25:272–278.

    External Resources

  23. Krenning EP, Valkema R, Kooij PPM, Breeman WAP, Bakker WH, deHerder WW, vanEijck CHJ, Kwekkeboom DJ, deJong M, Pauwels S: Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S219–S223.
  24. Guillemin R: Somatostatin: The early days. Metabolism 1993;41 (suppl 2):1–4.
  25. Pless J, Bauer W, Briner U, Doepner W, Marbach P, Maurer R, Petcher TJ, Reubi J-C, Vonderscher J: Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol 1986;21 (suppl 119):54–64.
  26. Ho LT, Chen RL, Chou TY, Fong JC, Wong PS, Chou CK: Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects – A two-compartment open model. Clin Physiol Biochem 1986;4:257–267.

    External Resources

  27. Marks N, Stern F: Inactivation of somatostatin (GH-RIH) and its analogs by crude and partially purified rat brain extracts. FEBS Lett 1975;55:220–224.
  28. Pless J: Chemical structure – Pharmacological profile of Sandostatin®; in O’Dorisio TM (ed): Sandostatin in the Treatment of GEP Endocrine Tumors. Berlin, Springer, 1989, pp 3–13.
  29. Vale W, Rivier J, Ling N, Brown M: Biologic and immunologic activities and applications of somatostatin analogs. Metabolism 1978;27(suppl 1):1391–1401.
  30. Battershill PE, Clissold SP: Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38:658–702.
  31. Camboni MG: Octreotide; in Braga PC, Guslandi M, Tittobello A (eds): Drugs in Gastroenterology. New York, Raven Press, 1991, pp 318–336.
  32. Scarpignato C: Octreotide, the synthetic long-acting somatostatin analogue: Pharmacological profile; in Scarpignato C (ed): Octreotide: From Basic Science to Clinical Medicine. Basel, Karger, 1996, pp 54–72.
  33. Eriksson B, Tiensuu Janson E, Bax NDS, Mignon M, Morant R, Opolon P, Rougier P, Öberg KE: The use of new somatostatin analogs, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumors. Digestion 1996;57(suppl 1):77–80.
  34. Lamrani A, Vidon N, Sogni P, Nepveux P, Catus F, Blumberg J, Chaussade S: Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol 1997;43:65–70.
  35. Barthomeuf C, Pourrat H, Pourrat A, Ibrahim H, Cottier PE: Stabilization of Octastatin, a somatostatin analogue: Comparative accelerated stability studies of two formulations for freeze-dried products. Pharm Acta Helv 1996;71:161–166.
  36. Veber DF, Freidlinger RM, Perlow DS, Paleveda WJ, Holly FW, Strachan RG, Nutt RF, Arison BH, Homnick C, Randall WC, Glitzer MS, Saperstein R, Hirschmann R: A potent cyclic hexapeptide analogue of somatostatin. Nature 1981;292:55–58.
  37. Huang Z, Probstl A, Spencer JR, Yamazaki T, Goodman M: Cyclic hexapeptide analogs of somatostatin containing bridge modifications. Syntheses and conformational analyses. Int J Pept Protein Res 1993;42:352–365.
  38. Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G: Disposition of Sandostatin, a new synthetic somatostatin analogue in rats. Drug Metab Dispos 1989;17:699–703.

    External Resources

  39. Marbach P, Briner U, Lemaire M, Schweitzer A, Terasaki T: From somatostatin to Sandostatin®: Pharmacodynamics and pharmacokinetics. Digestion 1993;54(suppl 1):9–13.
  40. Chanson P, Timsit J, Harris AG: Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumors. Clin Pharmacokinet 1993;25:375–391.
  41. Pless J: Chemical structure – Pharmacological profile of Sandostatin®; in O’Dorisio TM (ed): Sandostatin in the Treatment of GEP Endocrine Tumors. Berlin, Springer, 1989, pp 3–13.
  42. Peters GE: Distribution and metabolism of exogenous somatostatin in rats. Regul Peptides 1982;3:361–369.
  43. Kutz K, Nusch E, Rosenthaler J: Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986;21(suppl 119):65–72.
  44. Longnecker SM: Somatostatin and octreotide: Literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intell Clin Pharm 1988;22:99–106.

    External Resources

  45. Wynick D, Bloom SR: The use of long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocr Metab 1991;73:1–3.

    External Resources

  46. Nicholls J, Wynick D, Domin J, Sandler LM, Bloom SR: Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. Clin Endocrinol 1990;32:545–550.
  47. Weeke J, Christensen SE, Orskov H, Kaal A, Pedersen MM, Illum P, Harris AG: A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. J Clin Endocr Metab 1992;75:163–169.

    External Resources

  48. Kallivretakis N, Yotis A, Del Pozo E, Marbach P, Mountokalakis T, et al: Pharmacokinetics of SMS 201-995 in normal subjects and in patients with severe renal failure. Neuroendocrinol Lett 1985;7:92.
  49. Kuhn JM, Basin C, Mollard M, de Rougé B, Baudoin C, Obach R, Tolis G: Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014. Eur J Clin Pharmacol 1993;45:73–77.
  50. Chassard D, Barbanoj M, Català M, Hawkins F, Moreiro J, et al: Pharmacokinetics of lanreotide. J Endocrinol Invest 1997;20(suppl 7):30–32.
  51. Robinson C, Castañer J: Lanreotide acetate. Drugs Future 1994;19:992–999.
  52. Lewin MJM, Le Romancer M: Somatostatin receptors; in Scarpignato C (ed): Octreotide: From Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 23–34.
  53. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157–198.
  54. Schonbrunn A: Somatostatin receptors: Present knowledge and future directions. Ann Oncol 1999;10 (suppl 2):S17–S21.
  55. Patel YC, Srikant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hSSTR 1–5). Endocrinology 1994;135:2814–2817.
  56. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB: The somatostatin receptor family. Life Sci 1995;57:1249–1265.

    External Resources

  57. Reubi JC: Octreotide and nonendocrine tumors: Basic knowledge and therapeutic potential; in Scarpignato C (ed): Octreotide: From Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 246–269.
  58. Hofland LJ, Lamberts SWJ: Somatostatin receptors and disease: Role of receptor subtypes. Baillières Clin Endocrinol Metab 1996;10:163–176.
  59. Lytras A, Tolis G: Clinical significance of tumor somatostatin receptor subtype expression. Rev Clin Pharmacol Pharmacokinet 1997;11:3–12.
  60. Virgolini I, Pangeri T, Bischof C, Smith-Jones P, Peck-Radosavljevic M: Somatostatin receptor subtype expression in human tissues: A prediction for diagnosis and treatment of cancer? Eur J Clin Invest 1997;27:645–647.
  61. Reubi JC, Landolt AM: High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocr Metab 1984;59:1148–1151.
  62. Ikuyama S, Nawata H, Kato KI, Ibayashi H, Nakagaki H: Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. J Clin Endocr Metab 1986;62:729–733.

    External Resources

  63. Folkman J: Tumour angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182–1186.
  64. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
  65. Lichtenbeld HHC, Van Dam Mieras MCE, Hillen HFP: Tumour angiogenesis: Pathophysiology and clinical significance. Neth J Med 1996;49:42–51.
  66. Denzler B, Reubi JC: Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 1999;85:188–198.
  67. Nakao-Hayashi J, Ito H, Kanayasu T, Morita I, Murota S: Stimulatory effects of insulin and insulin-like growth factor 1 on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992;92:141–149.
  68. Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42–49.
  69. Baserga R: The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 1995;55:249–252.
  70. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Öberg K: Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1977;36:607–614.
  71. Christensen ES, Weeke J, Ørskov H, Moller N, Flyvbjerg A, Harris AG, Lund E, Jorgensen J: Continuous subcutaneous pump infusion of somatostatin analogue SMS 201- 995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol 1987;27:297–306.
  72. Timsit J, Chanson PH, Larger E, Duet M, Mosse A, Guillausseau PJ, Harris AG, Moulonguet M, Warnet A, Lubetzki J: The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly. Acta Endocrinol 1987;116:108–112.

    External Resources

  73. Tauber P, Babin T, Tauber MT, Vigoni F, Bonafe A, Ducasse M, Harris AG, Bayard F: Long-term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab 1989;68:917–924.
  74. Roelfsema F, Frolich M, de Boer H, Harris AG: Octreotide treatment in acromegaly: A comparison between pen-treated and pump-treated patients in a cross-over study. Acta Endocrinol 1991;125:43–48.

    External Resources

  75. James RA, Chatterjee S, White MC, Hall K, Moller N, Kendall Taylor P: Comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly. Eur J Clin Invest 1992;22:554–561.
  76. Invitti C, Fatti LM, Cavagnini F, Ørskov H, Porcu L, Camboni MG: Octreotide nasal power in acromegalic patients: A dose-range and tolerability study. J Endocrinol Invest 1994;17(suppl 2):A41.
  77. Gillis JC, Noble S, Goa KL: Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;63:681–699.
  78. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, Lamberts SWJ, Marbach P, Ørskov H, Pagani G, Sheppard M, Simionescu L: Sandostatin LAR®: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995;44(suppl 1):18–26.
  79. Simionescu L, Boanta C, Dumitrache C, Mitrea M, Popa O, Bruns C, Marbach P, Lancrajan I: Sandostatin LAR: Pharmacokinetics, tolerability and efficacy in 24 acromegalic patients. J Endocrinol Invest 1993;16(suppl 1):148A.
  80. Helse J, Kvistborg A, Lancrajan I, Bruns C, Jervell J: Sandostatin LAR in acromegalic patients: A dose range and tolerability study. J Endocrinol Invest 1993;16(suppl 1):24A.
  81. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600–606.
  82. Kuhn JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F: Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994;38:213–219.

    External Resources

  83. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM: Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721–727.
  84. Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P: Slow-release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994;79:145–151.
  85. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F: Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20–26.
  86. Soule S, Conway G, Hatfield A, Jacobs H, Giusti M, Gussoni G, Cuttica CM, Giordano G: Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicentre study. J Clin Endocrinol Metab 1996;81:4502–4503.
  87. Colao A, Marzullo P, Ferone D, Marino V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G: Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 1999;22:40–47.
  88. Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR: Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 1999;22:409–418.
  89. Giusti M, Gussoni G, Cuttica CM, Giordano G, Italian Multicenter Slow Release Lanreotide Study Group: Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. J Clin Endocrinol Metab 1996;81:2089–2097.
  90. Scarpignato C, Modlin IM: The place of octreotide in the medical management of neuroendocrine gut tumors; in Scarpignato C (ed): Octreotide: From Basic Science to Clinical Medicine. Basel, Karger, 1996, pp 214–232.
  91. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond J-M, Dupas J-L, Gouerou H, Jian R, Genestin E, Bernades P, Rougier P: Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 1996;39:279–283.
  92. Bajetta E, Carnaghi C, Ferrari L, Spagnoli I, Mazzaferro V, Buzzoni R: The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumors. Digestion 1996;57(suppl 1):72–76.
  93. Tomassetti P, Migliori M, Gullo L: Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998;93:1468–1471.

    External Resources

  94. Wymenga ANM, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJDG, Fiasse RH, Valimaki MJ, Renstrup J, De Vries EGE, Öberg KE: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111–1117.
  95. Anthony LB: Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S216–S218.
  96. Mason-Garcia M, Vaccarella M, Horvath J, Redding TW, Groot K, Orsolini P, Schally AV: Radioimmunoassay for octapeptide analogs of somatostatin: Measurement of serum levels after administration of long-acting microcapsule formulations. Proc Natl Acad Sci USA 1988;85:5688–5692.
  97. Rothen-Weinhold A, Besseghir K, De Zelicourt Y, Gurny R: Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue. J Control Release 1998;52:205–213.

    External Resources

  98. Öberg K, Tiensuu Janson E, Eriksson B: Tumour markers in neuroendocrine tumors. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S160–S162.
  99. Vekemans M-C, Urbain J-L, Charkes D: Advances in radio-imaging of neuroendocrine tumors. Curr Opin Oncol 1995;7:63–67.
  100. Doppman JL, Jensen RT: Localization of gastroenteropancreatic tumors by angiography. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S163–S166.
  101. Kolby L, Wangberg B, Ahlman H, Tisell LE, Fjalling M, Forssell-Aronsson E, Nilsson O: Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 1998;22:679–683.
  102. Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William-Olsson L, Fjalling M, Forssell-Aronsson E, Ahlman H: Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998;77:632–637.
  103. Janson ET, Gobl A, Kalkner KM, Öberg K: A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 1996;56:2561–2565.
  104. Krenning EP, Bakker WH, Kooij PPM, Breman WAP, Oei HY, de Jong M, Reubi JC, Visser TJ, Kwekkeboom DJ, Reijs AEM, Van Hagen PM, Koper JW, Lamberts SWJ: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide in man: Metabolism, dosimetry and comparison with [123I-Tyr3]-octreotide. J Nucl Med 1992;33:652–658.
  105. Bakker WH, Alberts R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP: [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vivo validation. Life Sci 1991;49:1583–1591.
  106. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ: 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: Preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 2000;41:1114–1119.
  107. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P: Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928–1936.
  108. Breeman WA, Hofland LJ, van der Pluijm M, von Koetsveld PM, de Jong M, Setyono-Itan B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SW: A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: Preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide. Eur J Nucl Med 1994;21:328–335.
  109. Thakur ML, John E, Li J, Reddy HR, Halmos G, Schally AV: Tc-99m-RC-160: A somatostatin analog for imaging prostate cancer – Comparison with I-125-RC-160 and In-111-octreotide. J Nucl Med 1995;36:92P.
  110. Virgolini I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Smith-Jones P: ‘MAURITIUS’: Tumor dose in patients with advanced carcinoma. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S227–S230.
  111. Schillaci O, Corleto VD, Annibale B, Scopinaro F, Delle Fave G: Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigrapy in gastro-entero pancreatic tumors. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S186–S189.
  112. Ohrvall U, Westlin JE, Nilsson S, Juhlin C, Rastad J, Lundqvist H, Akerstrom G: Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy. Cancer 1997;80(suppl):2490–2494.
  113. Adams S, Baum RP, Hertel A, Wenisch HJC, Staib-Sebler E, Herrmann G, Encke A, Hor G: Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 1998;39:1155–1160.
  114. Benevento A, Dominioni L, Carcano G, Dionigi R: Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe. Semin Surg Oncol 1998;15:239–244.
  115. Schneebaum S, Even Sapir E, Cohen M, Shacham-Lehrman H, Gat A, Brazovsky E, Livshitz G, Stadler J, Skornick Y: Clinical applications of gamma-detection probes – Radioguided surgery. Eur J Nucl Med 1999;26(suppl):S26–S35.
  116. de Jong M, Breeman WAP, Bernard BF, Rolleman EJ, Hofland LJ, Visser TJ, Setyono-Han B, Bakker WH, Van der Puijm ME, Krenning EP: Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med 1995;22:608–616.
  117. Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, Macke HR: Gallium-67/gallium-68-[DFO]-octreotide – A potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: Synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317–325.
  118. Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch-MJ: In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med 1995;36:2315–2325.
  119. Anderson CJ, Jones LA, Bass LA, Sherman ELC, McCarthy DW, Cutler PD, Lanahan MV, Cristel ME, Lewis JS, Schwarz SW: Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med 1998;39:1944–1951.
  120. Wester HJ, Brockmann J, Rosch F, Wutz W, Herzog H, Smith-Jones P, Stolz B, Bruns C, Stocklin G: PET-pharmacokinetics of (18)F-octreotide: A comparison with (67)Ga-DFO- and (86)Y-DTPA-octreotide. Nucl Med Biol 1997;24:275–286.
  121. Eriksson B, Örlefors A, Sundin A, Skogseid B, Långström B, Bregström M, Öberg K: Positron emission tomography in neuroendocrine tumors. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S167–S171.
  122. Thakur ML: Radiolabelled peptides: Now and the future. Nucl Med Commun 1955;16:724–732.
  123. Schwartz AL, Frodovich SE, Lodish HF: Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J Biol Chem 1982;257:4230–4237.
  124. Duncan JR, Stephenson MT, Wu HP, Anderson CJ: Indium- 111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659–671.
  125. de Jong M, Bakker WH, Krenning EP, Breeman WAP, Van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Behe M, Powell P, Macke HR: Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0-D-Phe1,Tyr3]-octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368–371.
  126. Hofland LJ, Breeman WAP, Krenning EP, de Jong M, Waaijers M, van Koetsveld PM, Mäcke HR, Lamberts SWJ: Internalization of [DOTA0, 125I-Tyr3]-octreotide by somatostatin receptor-positive cells in vitro and in vivo: Implications for somatostatin-targeted radioguided surgery. Proc Assoc Am Physicians 1999;111:63–69.
  127. de Jong M, Bernard BF, de Bruin E, van Gameren A, Bakker WH, Visser TJ, Mäcke HR, Krenning EP: Internalization of [DTPA0]octreotide and of [DOTA0,Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998;19:283–288.
  128. Stolz B, Smith-Jones P, Albert R, Weckbeker G, Bruns C: New somatostatin analogues for radiotherapy of somatostatin receptor expressing tumors. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S224–S226.
  129. Krenning EP, Valkema R, Kooij PPM, Breeman WAP, Bakker WH, deHerder WW, vanEijck CHJ, Kwekkeboom DJ, deJong M, Pauwels S: Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol 1999;31 (suppl 2):S219–S223.
  130. Otte A, Müller-Brand J, Dellas S, Nitzsche EU, Hermann R, Mäcke HR: Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 1998;351:417–418.
  131. Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, Vorbeck F, Niederle B, Herold C, Virgolini I: Response to treatment with yttrium-90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 1998;39:2090–2094.
  132. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P: Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928–1936.
  133. Reubi JC, Schaer JC, Waser B, Hoeger C, Rivier J: A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. Eur J Pharmacol 1998;345:103–110.
  134. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM: Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998;282:737–740.
  135. Hirschmann R, Nicolaou KC, Pietranico S, Leaby EM, Salvino J, Arison B, Clichy MA, Spoors PG, Shakespeare WC, Sprengeler PA, Hamley P, Smith AB III, Reisine T, Raynor K, Maechler L, Donaldson C, Vale W, Freidinger RM, Cascieri MR, Strader CD: Nonpeptidal peptidomimetics with a β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P agonist. J Am Chem Soc 1992;114:9217–9218.
  136. Hirschmann R, Nicolaou K, Pietranico S, Salvino J, Leahy EM, Sprengeler PA, Furst G, Smith AB III: De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing β-D-glucose as a novel scaffolding. J Am Chem Soc 1993;115:12550–12568.
  137. Damour D, Barreau M, Blanchard J, Burgevin M-C, Doble A, Herman F, Pantel G, James-Surcouf E, Vuilhorgne M, Mignani S, Poitout L, Le Merrer Y, Depezay J-C: Design, synthesis and binding affinities of novel non-peptide mimics of somatostatin/sandostatin. Bioorg Med Chem Lett 1996;6:1667–1672.
  138. Pasternak A, Pan Y, Marino D, Sanderson PE, Mosley R, Rohrer SP, Birzin ET, Huskey SEW, Jacks T, Schleim KD, Cheng K, Schaeffer JM, Patchett AA, Yang L: Potent, orally bioavailable somatostatin agonists: Good absorption achieved by urea backbone cyclization. Bioorg Med Chem Lett 1999;9:491–496.
  139. Gillespie TJ, Erenberg A, Kim S, Dong J, Taylor JE, Hau V, Davis TP: Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther 1998;285:95–104.
  140. Magrath T: Targeted approaches to cancer therapy. Int J Cancer 1994;56:163–166.
  141. Schally AV, Nagy A: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1–14.
  142. Nagy A, Schally AV, Halmos G, Armatis P, Cai R-Z, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z: Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Assoc Sci USA 1998;95:1794–1799.
  143. Radulovic S, Nagy A, Szoke B, Schally AV: Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett 1992;62:263–271.
  144. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K: Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analog AN-238. Cancer Res 1999;59:1947–1953.

    External Resources

  145. Blum HE: Molecular biology and gene therapy in gastroenterology and hepatology. Eur J Gastroenterol Hepatol 1999;11:1–7.
  146. Roth JA, Cristiano J: Gene therapy for cancer: What have we done and where are we going? J Natl Invest 1999;89:21–36.
  147. Wake N, Kondoh H, Katoh H: Recent advances and perspective insights of gene therapy. Acta Obstet Gynaecol Jpn 1999;51:715–724.
  148. Caplen NJ: Gene therapy: Different strategies for different applications. Mol Med Today 1998;4:374–375.
  149. Farzaneh F, Trefzer U, Sterry W, Walden P: Gene therapy of cancer. Immunol Today 1998;19: 294–296.

    External Resources

  150. Rochaix P, Delesque N, Esteve J-P, Saint Laurent N, Voigt JJ, Vaysse N, Susini C, Buscail L: Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999;10:995–1008.
  151. Delesque N, Buscail L, Esteve JP, Saint Laurent N, Muller C, Weckbecker G, Bruns C, Vaysse N, Susini C: sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997;57:956–962.
  152. Rogers BE, Garver RI, Grizzle WE, Buchsbaum DJ: Genetic induction of antigens and receptors as targets for cancer radiotherapy. Tumor Targeting 1998;3:122–137.
  153. Scarpignato C: Somatostatin analogs in cancer management. Chemotherapy 2001;47(suppl 2):1–198.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50